Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 177

1.

Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors.

Kikuchi T, Toyota M, Itoh F, Suzuki H, Obata T, Yamamoto H, Kakiuchi H, Kusano M, Issa JP, Tokino T, Imai K.

Oncogene. 2002 Apr 18;21(17):2741-9.

2.

Heterogeneity in the modification and involvement of chromatin components of the CpG island of the silenced human CDH1 gene in cancer cells.

Koizume S, Tachibana K, Sekiya T, Hirohashi S, Shiraishi M.

Nucleic Acids Res. 2002 Nov 1;30(21):4770-80.

3.

Aberrant methylation of p57KIP2 gene in lung and breast cancers and malignant mesotheliomas.

Kobatake T, Yano M, Toyooka S, Tsukuda K, Dote H, Kikuchi T, Toyota M, Ouchida M, Aoe M, Date H, Pass HI, Doihara H, Shimizu N.

Oncol Rep. 2004 Nov;12(5):1087-92.

PMID:
15492797
4.
5.

Aberrant methylation of the Cyclooxygenase 2 CpG island in colorectal tumors.

Toyota M, Shen L, Ohe-Toyota M, Hamilton SR, Sinicrope FA, Issa JP.

Cancer Res. 2000 Aug 1;60(15):4044-8.

6.

Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer.

Soejima H, Nakagawachi T, Zhao W, Higashimoto K, Urano T, Matsukura S, Kitajima Y, Takeuchi M, Nakayama M, Oshimura M, Miyazaki K, Joh K, Mukai T.

Oncogene. 2004 May 27;23(25):4380-8.

PMID:
15007390
7.

DNA hypermethylation and histone hypoacetylation of the HLTF gene are associated with reduced expression in gastric carcinoma.

Hamai Y, Oue N, Mitani Y, Nakayama H, Ito R, Matsusaki K, Yoshida K, Toge T, Yasui W.

Cancer Sci. 2003 Aug;94(8):692-8.

8.

Transcriptional silencing of hedgehog-interacting protein by CpG hypermethylation and chromatic structure in human gastrointestinal cancer.

Taniguchi H, Yamamoto H, Akutsu N, Nosho K, Adachi Y, Imai K, Shinomura Y.

J Pathol. 2007 Oct;213(2):131-9.

PMID:
17724792
9.
10.

Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.

Strathdee G, Davies BR, Vass JK, Siddiqui N, Brown R.

Carcinogenesis. 2004 May;25(5):693-701. Epub 2004 Jan 16.

PMID:
14729589
11.

Silencing effect of CpG island hypermethylation and histone modifications on O6-methylguanine-DNA methyltransferase (MGMT) gene expression in human cancer.

Nakagawachi T, Soejima H, Urano T, Zhao W, Higashimoto K, Satoh Y, Matsukura S, Kudo S, Kitajima Y, Harada H, Furukawa K, Matsuzaki H, Emi M, Nakabeppu Y, Miyazaki K, Sekiguchi M, Mukai T.

Oncogene. 2003 Dec 4;22(55):8835-44.

PMID:
14647440
13.

Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma.

Mitani Y, Oue N, Hamai Y, Aung PP, Matsumura S, Nakayama H, Kamata N, Yasui W.

J Pathol. 2005 Jan;205(1):65-73.

PMID:
15586362
14.

Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas.

Kanaseki T, Ikeda H, Takamura Y, Toyota M, Hirohashi Y, Tokino T, Himi T, Sato N.

J Immunol. 2003 May 15;170(10):4980-5.

15.

Epigenetic inactivation of CHFR in human tumors.

Toyota M, Sasaki Y, Satoh A, Ogi K, Kikuchi T, Suzuki H, Mita H, Tanaka N, Itoh F, Issa JP, Jair KW, Schuebel KE, Imai K, Tokino T.

Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7818-23. Epub 2003 Jun 16.

16.

DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers.

Satoh A, Toyota M, Itoh F, Kikuchi T, Obata T, Sasaki Y, Suzuki H, Yawata A, Kusano M, Fujita M, Hosokawa M, Yanagihara K, Tokino T, Imai K.

Br J Cancer. 2002 Jun 5;86(11):1817-23.

17.

Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning.

Hinshelwood RA, Melki JR, Huschtscha LI, Paul C, Song JZ, Stirzaker C, Reddel RR, Clark SJ.

Hum Mol Genet. 2009 Aug 15;18(16):3098-109. doi: 10.1093/hmg/ddp251. Epub 2009 May 28.

PMID:
19477956
18.
19.

Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.

Tada Y, Brena RM, Hackanson B, Morrison C, Otterson GA, Plass C.

J Natl Cancer Inst. 2006 Mar 15;98(6):396-406.

PMID:
16537832
20.

Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.

Schagdarsurengin U, Gimm O, Hoang-Vu C, Dralle H, Pfeifer GP, Dammann R.

Cancer Res. 2002 Jul 1;62(13):3698-701.

Supplemental Content

Support Center